+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Pembrolizumab"

Head and Neck Cancer (HNC) Pipeline Analysis Report - Product Thumbnail Image

Head and Neck Cancer (HNC) Pipeline Analysis Report

  • Report
  • August 2024
  • 150 Pages
  • Global
From
Gastric Cancer Pipeline Analysis Report - Product Thumbnail Image

Gastric Cancer Pipeline Analysis Report

  • Report
  • August 2024
  • 150 Pages
  • Global
From
From
From
From
From
From
From
From
From
From
From
From
From
From
From
From
Oncology Drug Market - Forecasts from 2025 to 2030 - Product Thumbnail Image

Oncology Drug Market - Forecasts from 2025 to 2030

  • Report
  • June 2025
  • 141 Pages
  • Global
From
Melanoma Cancer Market in Australia - Product Thumbnail Image

Melanoma Cancer Market in Australia

  • Report
  • May 2026
  • 151 Pages
  • Australia
From
Melanoma Cancer Market in Germany - Product Thumbnail Image

Melanoma Cancer Market in Germany

  • Report
  • May 2026
  • 154 Pages
  • Germany
From
Loading Indicator

Pembrolizumab is a type of oncology drug used to treat certain types of cancer. It is a monoclonal antibody, which works by targeting and blocking a protein called PD-1, which is found on the surface of some cancer cells. This helps the body's immune system to recognize and attack the cancer cells. Pembrolizumab is used to treat a variety of cancers, including melanoma, non-small cell lung cancer, head and neck cancer, Hodgkin lymphoma, and urothelial carcinoma. It is also used in combination with other drugs to treat certain types of advanced or metastatic cancers. Pembrolizumab is approved by the US Food and Drug Administration (FDA) and is available in the US and other countries. It is typically administered intravenously, and the dosage and duration of treatment depend on the type and stage of cancer being treated. Some companies in the Pembrolizumab market include Merck & Co., Inc., Bristol-Myers Squibb, AstraZeneca, and Roche. Show Less Read more